What question did this study set out to answer?

This research aims to evaluate a metabolic network biomarker for diagnosing dementia with Lewy bodies (DLB) across stages.

Metabolic brain networks in dementia with Lewy bodies: from prodromal to manifest disease stages

View Full Paper

Ask AI

Bookmark

Authors

Multivariate analysis demonstrates FDG PET distinguishes DLB from other dementias and predicts clinical outcomes.

This research aims to evaluate a metabolic network biomarker for diagnosing dementia with Lewy bodies (DLB) across stages.
Analysed clinical and imaging data from 1180 participants across 14 tertiary centres and multicentre datasets.
Calculated DLBRP, ADRP, and PDRP from imaging scans.
Compared results across different patient groups, including DLB, MCI-LB, Addison’s Disease, and normal controls.
DLBRP distinguished DLB from normal controls with >89% sensitivity and >90% specificity.
Scores correlated with clinical measurements, including the Mini–Mental State Examination and Unified Parkinson’s Disease Rating Scale.
Elevated DLBRP scores observed in mild cognitive impairment-LB, indicating early detection potential.

Kramberger et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark